Gabriel García

Lab Technician at Stämm Biotech

Gabriel García has three years of professional experience. In 2016, they began their career as an Undergraduate Student Researcher at Universidad de Buenos Aires. In 2020, they joined ICON plc, where they served as a Clinical Research Associate I (CRA I), Site Management Associate, and Clinical Data Coordinator. In 2022, they began their current role as a Lab Technician at Stämm Biotech.

Gabriel García completed their Bachelor's Degree in Biological Sciences, Molecular Biology from the University of Buenos Aires between 2013 and 2019. Gabriel then obtained a Clinical Trial Monitoring course from FEFyM in May 2021 and an FCE from the University of Cambridge in June 2013.

Links


Org chart

This person is not in the org chart


Teams


Offices

This person is not in any offices


Stämm Biotech

Stämm is a biotechnology company dedicated to making biomanufacturing easy, scalable, and repeatable. We have developed the first methodology for continuous industrial production of biologics and cell therapies leveraging microfluidics and 3D printing. In 2020, the total volume of anthropogenic mass matched the total amount of biomass globally, which means it matched everything that is alive on the planet. We can only expect that this number keeps increasing since it's key to solving humanity's systemic challenges. But we have to make sure that conquering the great challenges of humanity doesn’t extinguish the planet’s capacity to sustain life. The current way of biomanufacturing has provided humanity with innumerable solutions. Bioprocessing is the most efficient way to align human advancement with a thriving nature. In order to prevent nature from perishing, we aim to put it at the center of all human activities by incorporating its knowledge system within the process of achieving humanity's prosperity. Founded in 2016, Stämm mimics nature’s use of laminar flow to down-size a whole biotech facility into an all-in-one, plug & play desktop unit. Our focus is to decentralize bioprocesses and democratize access to biotechnology products, thus freeing our partners to focus on the disruptive discoveries that make an impact on people’s life.


Industries

Employees

51-200

Links